Streetbeat News

Regulatory

GLASF

Glass House Brands, a low-cost cannabis producer in the U.S., is positioned for growth as it raises funds for expansion. Its large-scale operations in California enable efficient production, and potential legal clarifications on cannabis could benefit its stock.

Portfolio Pulse from

January 13, 2025 | 5:00 am

BNO

Goldman Sachs Global Commodities Research co-head Daan Struyven discusses the impact of sanctions on the Russian oil industry and their potential effects on Brent crude oil prices.

Portfolio Pulse from

January 13, 2025 | 3:15 am

FXI

The article discusses the potential impact of a real estate collapse in China, which could be more severe than the American housing crisis. Despite China's stock market success in 2024, the looming housing crisis and potential trade war make the risk/return ratio unattractive. The government is seeking ways to stimulate the economy.

Portfolio Pulse from

January 13, 2025 | 1:30 am

NTRS

The National University of Singapore (NUS), Northern Trust, and UOB have launched a pioneering initiative to tokenize green bond credentials using blockchain technology. This marks a significant step in green finance innovation, enhancing transparency and data integrity in ESG reporting.

Portfolio Pulse from

January 13, 2025 | 1:15 am

MSOS

The AdvisorShares Pure US Cannabis ETF (MSOS) has dropped 65% over the past year, affected by Florida's failed legalization vote and MJUS liquidation. The ETF is poorly diversified, with top holdings making up 70% of the fund. Potential redemptions could add pressure, but changes in 280E taxation might offer a rebound opportunity.

Portfolio Pulse from

January 13, 2025 | 1:00 am

CRBU

Caribou Biosciences has initiated the CB-010 GALLOP Phase 1 trial for lupus and is progressing with the CB-012 AMpLify Phase 1 trial for r/r AML, with no dose-limiting toxicities observed at dose level 3. The company anticipates multiple clinical datasets in 2025.

Portfolio Pulse from

January 13, 2025 | 12:15 am

CVNA

Levi & Korsinsky has initiated an investigation into Carvana Co. for potential violations of federal securities laws following a report by Hindenburg Research.

Portfolio Pulse from

January 12, 2025 | 5:30 pm

XGN

Exagen Inc. has received conditional approval from the New York State Department of Health for new lupus and rheumatoid arthritis biomarkers, with a commercial launch planned for January 2025. Preliminary 2024 financial results show record revenue and improvements in adjusted EBITDA and cash burn.

Portfolio Pulse from

January 12, 2025 | 5:15 pm

AVXL

Anavex's Alzheimer's drug, Blarcamesine, has been accepted for evaluation by the EMA, with a decision expected by December 2025. The drug shows a 92% likelihood of approval and significantly slows cognitive decline by 36%.

Portfolio Pulse from

January 12, 2025 | 4:30 pm

JNJ

Levi & Korsinsky is investigating Johnson & Johnson for potential securities fraud related to a temporary pause in their VARIPULSE™ cases due to reported neurovascular events.

Portfolio Pulse from

January 12, 2025 | 4:15 pm